Study Population | With influenza IgM positive (n = 73) | Without influenza IgM positive (n = 67) | Total (n = 140) | P value |
---|---|---|---|---|
Treatment in hospital | ||||
 Oxygen Therapy | ||||
 Nasal Cannula | 32 (43.8) | 29 (43.3) | 61 (43.6) | 0.9475 |
 Oxygen Mask | 1 (1.4) | 2 (3.0) | 3 (2.1) | 0.5069 |
 NMV/High-flow nasal cannula | 35 (47.9) | 34 (50.7) | 69 (49.3) | 0.7405 |
 IMV/ECMO | 7 (9.6) | 5 (7.5) | 12 (8.6) | 0.6535 |
 Drugs | ||||
  Oseltamivir | 33 (45.2) | 23 (34.3) | 56 (40.0) | 0.1894 |
  Arbidol | 53 (72.6) | 47 (70.1) | 100 (71.4) | 0.7482 |
  Compound Methoxamine capsule | 17 (23.3) | 6 (9.0) | 23 (16.4) | 0.0222 |
Clinical outcomes | ||||
 CURB-65 |  |  |  | 0.0397 |
  Low risk | 65 (89.0) | 50 (74.6) | 115 (82.1) | |
  Medium risk | 6 (8.2) | 8 (11.9) | 14 (10.0) | |
  High risk | 2 (2.7) | 9 (13.4) | 11 (7.9) | |
 Duration of viral shedding, days | 26.0 (20.0, 32.0) | 25.0 (21.0, 32.0) | 25.5 (20.5, 32.0) | 0.9694 |
 Hospital length of stay, days | 13.0 (10.0, 18.0) | 14.0 (10.0, 17.0) | 13.0 (10.0, 18.0) | 0.9084 |
 Time from illness onset to discharge, days | 27.0 (22.0, 35.0) | 27.0 (21.0, 33.0) | 27.0 (22.0, 33.5) | 0.6208 |
 Death,No (%) |  |  |  | 0.0276 |
  Discharge | 70 (95.9) | 57 (85.1) | 127 (90.7) | |
  Death | 3 (4.1) | 10 (14.9) | 13 (9.3) |